Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK. Grommes C, et al. Among authors: viale a. Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19. Blood. 2019. PMID: 30567753 Free PMC article. Clinical Trial.
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
Shah GD, Socci ND, Gold JS, Wolchok JD, Carvajal RD, Panageas KS, Viale A, Brady MS, Coit DG, Chapman PB. Shah GD, et al. Among authors: viale a. Ann Oncol. 2010 Aug;21(8):1718-1722. doi: 10.1093/annonc/mdp593. Epub 2010 Jan 15. Ann Oncol. 2010. PMID: 20080829 Free article. Clinical Trial.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA. Morris LG, et al. Among authors: viale a. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19024-9. doi: 10.1073/pnas.1111963108. Epub 2011 Nov 7. Proc Natl Acad Sci U S A. 2011. PMID: 22065749 Free PMC article.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA. Turcan S, et al. Among authors: viale a. Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866. Nature. 2012. PMID: 22343889 Free PMC article.
Genome sequencing identifies a basis for everolimus sensitivity.
Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB. Iyer G, et al. Among authors: viale a. Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23. Science. 2012. PMID: 22923433 Free PMC article.
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB. Abdel-Wahab O, et al. Among authors: viale a. Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3. Cancer Discov. 2014. PMID: 24589925 Free PMC article.
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.
Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, Russo P, Cheng EH, Motzer RJ, Berger MF, Hsieh JJ. Voss MH, et al. Among authors: viale a. Clin Cancer Res. 2014 Apr 1;20(7):1955-64. doi: 10.1158/1078-0432.CCR-13-2345. Epub 2014 Mar 12. Clin Cancer Res. 2014. PMID: 24622468 Free PMC article.
Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.
Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, McKeithan T, Sander C, Tam W, Seshan VE, Chan WC, Chaganti RS, Wendel HG. Oricchio E, et al. Among authors: viale a. J Exp Med. 2014 Jun 30;211(7):1379-91. doi: 10.1084/jem.20132120. Epub 2014 Jun 9. J Exp Med. 2014. PMID: 24913233 Free PMC article.
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, Socci ND, Viale A, Schwartz GK, Reuter V, Bochner BH, Rosenberg JE, Bajorin DF, Berger MF, Petrini JH, Solit DB, Taylor BS. Al-Ahmadie H, et al. Among authors: viale a. Cancer Discov. 2014 Sep;4(9):1014-21. doi: 10.1158/2159-8290.CD-14-0380. Epub 2014 Jun 16. Cancer Discov. 2014. PMID: 24934408 Free PMC article.
378 results